NOVO NORDISK A/S (NVO): what the price assumes

Generated: 2026-07-29 · Exported: 2026-08-01 · Source: https://boothcheck.com/report/NVO

Headline

Field	Value
Ticker	NVO
Company	NOVO NORDISK A/S
Sector / Industry	Healthcare
Current price	$51.25/sh
Composition	Diabetes care 67% / Obesity care 27% / Rare blood disorders 4% / Rare endocrine disorders 2% / Other Rare disease 1%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

Field	Value
Inversion basis	whole-company
Operating margin (value-band context)	6.2%
Operating margin today	41.3%
Margin compression (value-band)	-35.1pp
Implied growth	-3.5%
Multiple paid	13x operating income

The operating-margin figure is value-band context at year 8: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 8.2% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~5.5pp.

Reconcile: at the x-ray's 9.3% required return this reads ~2.2%/yr; the models below use their own rates.

How unusual the bet is: within-range (limited comparison data)

Reference	Value
vs own history	-1.13σ
implied end-window share	0%

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Family	Median price/FV	Models	Reads
Asset	1.40x	5	expensive
Earnings	1.71x	4	expensive
Relative	0.65x	5	justifies
Growth	0.74x	4	justifies

Families that justify the price: Relative, Growth Families that call it expensive: Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.8%); the inversion above states its own rate.

Per-Model Detail (n=18)

Model	Family	FV	Price/FV	Applicable	Methodology
DCF Perpetual Growth	Growth	$138.12	0.37x	yes	FCF base $16.9B, growth 22% (input: historical growth), terminal g 4.0%, WACC 8.8%, 7yr projection
DCF Exit Multiple	Growth	$80.34	0.64x	yes	Exit EV/EBITDA: 9.6x / 11.6x / 13.6x (bear / base = today's held flat / bull), 7yr
Relative Valuation	Relative	$84.76	0.60x	yes	P/E 24x (static sector reference · 2026-04), scenarios: 19.3x / 24.0x / 28.7x (bear / base = reference held flat / bull), EV/EBITDA 16x
Simple DDM	Growth	—	—	no	—
Two-Stage DDM	Growth	$60.76	0.84x	yes	Stage 1: 20% for 5yr, Stage 2: 3.5% perpetual
Simple Excess Return	Asset	$36.65	1.40x	yes	BV/sh $6.42, ROE (TTM) 52.8%, ke 9.3%
Two-Stage Excess Return	Asset	$109.78	0.47x	yes	5yr excess ROE then converge to ke=9.3%
Discounted Future Market Cap	Growth	$60.90	0.84x	yes	Rev $45.5B, growth 22% (input: historical growth; tapered), Terminal P/S: 4.0x / 5.0x / 6.0x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair Value	Relative	$79.11	0.65x	yes	EPS $3.39, growth 23% (input: historical EPS growth), PEG=0.65 (Undervalued)
Margin Trajectory	Growth	—	—	no	—
Earnings Power Value	Earnings	$25.40	2.02x	yes	Normalized EBIT (5y avg op income, one-time charges added back) $14.47B × (1−22%) / WACC 8.8% → EPV (no growth)
Residual Income	Asset	$59.59	0.86x	yes	BV $6.42 + 5yr PV of (ROE (TTM) 52.8% − Kₑ 9.3%) × BV; BV grows 8.8%/yr
Graham Number	Asset	$22.14	2.31x	yes	√(22.5 × EPS $3.39 × BVPS $6.42) — Graham's conservative floor
EV/EBITDA Relative	Relative	$71.84	0.71x	yes	EBITDA $20.93B × sector EV/EBITDA 16.0x
FCF Yield	Earnings	$17.57	2.92x	yes	FCF $8670.9M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF Yield	Earnings	—	—	no	—
Ben Graham Formula	Earnings	$109.42	0.47x	yes	EPS $3.39 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/B	Asset	$24.22	2.12x	yes	BV $6.42 × (ROIC 33.3% / WACC 8.8%)
P/Sales Sector	Relative	$40.92	1.25x	yes	Revenue $45.45B × sector P/S 4.0x
PEG Fair Value	Relative	$118.67	0.43x	yes	EPS $3.39 × (PEG 1.5 × growth 23.3% (input: historical EPS growth)) → PE 35.0x
Earnings Yield	Earnings	$36.66	1.40x	yes	EPS $3.39 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations Multiple	Relative	—	—	no	—
Clinical Phase NPV	Growth	—	—	no	—
Merton	Asset	—	—	no	—
V5 Mechanical	—	—	—	no	—

Solvency

Field	Value
Net debt	$17.8b
Net debt / NOPAT (after-tax)	1.16x
Net debt / operating income (pre-tax)	0.91x
Interest coverage	30.3x
Share count CAGR (buyback)	-0.8%
Burning cash	no

Bullet Takeaways

• Obesity care accounts for 27% of revenue against 67% for diabetes care, so almost the entire company rests on one molecule family and whatever succeeds it.
• The oral form of Wegovy, the first GLP-1 pill cleared for obesity in the United States, sold DKK 2.3 billion in its first quarter on the market at a launch cash price of $149 a month for the starting dose.
• Guidance for 2026 is for adjusted sales and operating profit to fall between 4% and 12% at constant exchange rates, a slightly narrower decline than the company first indicated, and the half-year report lands on August 5, 2026.

Bull Case

A business can be cheap and disappointing at the same time. Novo Nordisk's own guidance for 2026 is for adjusted sales and operating profit to fall between 4% and 12% at constant exchange rates, and the shares are priced as though that is roughly the permanent condition. The bull case is not that the boom resumes. It is that a shrinking year is not a shrinking decade, and the price has stopped asking for either.

The reason to think so starts with a pill. Novo launched the oral form of Wegovy in the United States in early January 2026, the first GLP-1 cleared for obesity that a patient swallows rather than injects, with the starting dose at $149 a month and the two highest doses at $299. It sold DKK 2.3 billion of it in the first quarter, roughly twice what analysts had penciled in. Pills reach places injections do not: primary care prescribing, cash-paying patients who never wanted a needle, and markets where cold chain distribution has quietly capped the category all along.

That launch is landing on a mix already tilting the right way. Obesity care accounts for 27% of revenue and diabetes care 67%, and the faster of the two is the one still adding share. Underneath both sits an operating margin of 41.3% on a trailing basis, earned while the company funds one of the most expensive manufacturing build-outs in the industry. Very few businesses of this size convert revenue at that rate, and the market is currently valuing the conversion as though it were ordinary.

The pipeline has not stopped either. CagriSema, the once-weekly combination of semaglutide with an amylin analogue, went to the FDA in December 2025 with a decision expected late in 2026. Away from metabolic disease, the haemophilia A antibody denecimig reported long-term phase 3 safety and efficacy data at the ISTH congress this summer. The rare disease franchises are a small slice of revenue, which is exactly why anything that works there reads as upside rather than defence.

Capital is being returned while the argument plays out. The company is repurchasing B shares under a programme of up to DKK 15 billion running from February 2026, with the current tranche extending into February 2027. The share count has been drifting down about 0.8% a year since the end of 2021.

Which leaves the bull with an unusually simple claim. When the price already assumes the operating line contracts, the buyer does not need the boom back, does not need CagriSema approved, and does not need US pricing to recover. Flat would do it.

Bear Case

The discount is not an accident, and the honest bear starts by explaining why the market applies it rather than assuming it is a mistake. Three forces are pulling at the same revenue line, and only one of them is competition.

The first is price, and it is already fixed. In November 2025 the company agreed with the US administration to sell injectable Ozempic and Wegovy at $245 a month for Medicare, to set starting doses of the obesity pills at $149 a month across Medicare, Medicaid and the government's direct-purchase site, and to offer existing weight-management GLP-1s to consumers at an average of about $350 a month for vials. Medicare covering obesity treatment for the first time is real incremental volume. But a price cut arrives in full on day one while volume arrives gradually, and the company said at the time that it expected global sales to decline by a low single-digit percentage in 2026 as a result.

The second is that semaglutide is already generic in a G7 country. Novo let its Canadian patent lapse over an unpaid maintenance fee, data exclusivity there ran out in January 2026, and Health Canada has since approved generic semaglutide from Dr. Reddy's and Apotex with further submissions under review. Canada by itself is not material to a company this size. What it is, is a live public demonstration of what happens to price and volume when this molecule loses protection, running several years ahead of the markets where it would actually matter.

The third is competition, and the news there has been genuinely bad. CagriSema, the follow-on injectable meant to leapfrog the current generation, produced 23% weight loss at 84 weeks in its head-to-head study but failed to show non-inferiority against Eli Lilly's tirzepatide at the top dose. On the oral side, Lilly's orforglipron is a small molecule rather than a peptide, which means no empty-stomach ritual for the patient and cheaper chemistry for the manufacturer, and Lilly has indicated pricing up to $399 a month with lower doses near the level of the Wegovy pill. Novo reached the market first with a pill. First and best are different claims.

Concentration turns each of those from a problem into a systemic one. Diabetes care is 67% of revenue and obesity care another 27%, and both rest on the same molecule and its descendants. There is no third leg here to absorb a shock to the first two.

Set that against the assumption already in the shares, and the shape of the risk becomes clear. The price needs contraction of only about 1.9% a year in operating profit before things settle, which is gentler than what the company has guided for this year. In other words the market is already treating 2026 as a trough rather than a trend. If it is a trend, the support disappears fast, because the lenses that value this business purely on what it earns today, crediting no growth at all, already sit below the price rather than above it.

There is a version of events where the discount is simply correct. A franchise whose best product is being priced down by governments, copied in one wealthy market already, and matched by a competitor's next molecule is not collapsing. It is re-rating toward something ordinary. For anyone who bought the extraordinary version, those amount to the same outcome.

Valuation

At $48.89, the market is paying about 12 times what this business earns from operations. The price needs operating profit to shrink only about 1.9% a year from here before settling into something slower and permanent, which is an assumption most large pharmaceutical companies never have attached to them. It is a valuation built on decay, not on compounding.

One basis note first. The accounts are in Danish kroner under IFRS, and the New York line is a depositary receipt standing one for one against the B shares listed in Copenhagen. The dollar figures here are translated; the kroner figures are the company's own, and the two move apart with the exchange rate rather than with the business.

The methods disagree in an unusual direction. Peer multiples put the price about 42% below where they land, and the cash-flow methods that credit forward earnings about 28% below, which is the signature of a business the market has decided to discount rather than one it is paying up for. The only lenses the price sits above are the ones that credit no growth whatsoever: the price sits about 1.6 times where the earnings power methods land, and about 1.3 times where the asset value methods land. Read together, the pattern says the market is not underwriting the obesity franchise compounding. It is underwriting a large, high-margin business declining in an orderly way.

How demanding is that assumption? Not very, measured against the company's own record: a contraction at that pace sits inside what it has recently delivered, and the awkward part is not the rate but the length of time it has to hold. The trailing operating margin is 41.3%, which tells you the decline being priced is a revenue and realized-price story rather than a cost story. Nothing in the price requires the manufacturing base to become less efficient.

The balance sheet does not constrain any of this. Net debt of $17.8 billion sits below a single year of operating profit, and the interest bill against it is trivial in the context of what the operations throw off. The share count has been coming down about 0.8% a year since the end of 2021, and the current buyback tranche runs into February 2027. A company this cash-generative and this lightly levered gets to make decisions on its own schedule.

What is most interesting about this price is what it does not require. No volume ramp for the pill, no approval for CagriSema, no recovery in US realized pricing. Those sit outside the arithmetic entirely. The corresponding exposure is that the gentle decline the price does assume turns out to have been the optimistic case.

Catalysts

The half-year report lands on August 5, 2026, and it is the first full read on the oral launch. Three lines in it matter more than the headline: the run rate of the Wegovy pill after its first partial quarter on the market, whether the 2026 guidance range narrows again after being tightened at the first quarter, and what the US pricing agreement is doing to realized price per prescription rather than to list price.

The larger dated event is the FDA decision on CagriSema, expected late in 2026 after the filing went in during December 2025. Approval matters less for the label itself than for what the company can charge, given how the head-to-head against tirzepatide read. Eli Lilly's oral orforglipron is the other clock: it has not launched yet, and every month it does not is a month the Wegovy pill has the US oral obesity market to itself.

Generics are the slow-moving item. Health Canada has approved semaglutide copies from two manufacturers with more submissions in the queue, and how quickly those take share in a single wealthy market is the best available preview of what happens elsewhere later.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• IDXX (IDEXX LABORATORIES INC /DE)
• FY2025 10-K: …operator of corporate hospital chains that also sells veterinary point-of-care diagnostic instruments. Consolidation among our competitors and our customers may intensify the competition we face. While we believe that our offerings are competitively differentiated due to our innovative products and services that…
• FY2025 10-K: …our competition, refer to "Part I, Item 1A. Risk Factors." Competitive factors in our different business areas are detailed below: • Companion animal diagnostic offerings . We compete primarily on the basis of ease of use and speed of our products, diagnostic accuracy, product quality, breadth of our product line and…
• ARGX (ARGX)
• FY2025 20-F: …factors that could cause our actual future results of operations and financial positions, prospects, developments, growth, business strategies, plans and our objectives for future operations, results of clinical trials and regulatory approvals to differ materially from those forecasted or suggested herein.…
• FY2025 20-F: …other pharmaceutical companies have mAbs or other biologics in clinical development for the treatment of autoimmune diseases. Currently, our commercial revenue is generated by VYVGART and VYVGART SC in gMG, CIDP and ITP (Japan only). We face and expect to continue to face intense competition from other…
• ALNY (ALNYLAM PHARMACEUTICALS, INC.)
• FY2025 10-K: …• patent position. Our competitors may develop or commercialize products with significant advantages over any products we or our collaborators develop based on any of the factors listed above or on other factors. In addition, our competitors may enter into collaborations with or receive funding from larger…
• FY2025 10-K: …the potential to become a leading therapy for ATTR amyloidosis and to significantly improve our gross margins on product sales and our non-GAAP operating income margin. Results of Operations The following table summarizes the results of our operations: Years Ended December 31, 2025 vs 2024 2024 vs 2023 (In thousands,…
• NBIX (NEUROCRINE BIOSCIENCES, INC.)
• FY2025 10-K: …immunological disorders. The accounting policies of the segment are the same as those described in the summary of significant accounting policies. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the Chief Executive Officer as chief…
• FY2025 10-K: …conflicts. General business and economic conditions that could affect our business, financial condition or results of operations include fluctuations in economic growth, inflation and interest rates, debt and equity capital markets, liquidity of the global financial markets, the availability and cost of credit,…
• NTRA (NATERA, INC.)
• FY2025 10-K: ​ 1,267 Gross margin ​ $ 1,493,180 ​ $ 1,023,158 ​ $ 492,740 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Gross margin percentage ​ ​ 64.7 % ​ ​ 60.3 % ​ ​ 45.5 % ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 128 Table of Contents ​ ​ 17. Subsequent Events Subsequent to December 31, 2025, the Company entered into a new lease arrangement for additional laboratory space…
• FY2025 10-K: …disclosure of incremental segment information on an interim and annual basis that are regularly provided to the chief operating decision maker (the "CODM") and included within each reported measure of segment profit or loss. The Company has adopted this ASU as of December 31, 2024. The Company currently operates as a…
• MRNA (Moderna, Inc.)
• FY2025 10-K: …market and distribute pharmaceutical products. In particular, the promotion, sales and marketing of healthcare items and services, as well as a wide range of pricing, discounting, structuring and commissions, certain customer incentive programs and other business arrangements, are subject to extensive laws designed…
• FY2025 10-K: …statements and the reported amounts of revenue and expenses during the reporting periods that are not readily apparent from other sources. Changes in our estimates are recorded in the financial results of the period in which the new information becomes available. The actual results that we experience may differ…
• RDNT (RadNet, Inc.)
• FY2025 10-K: …high and lesions can be difficult to find, such as in screening mammography. AI can also improve business processes to better effectively serve customers and improve reimbursement and collections accuracy. Competition Our competitors include independent imaging operators and smaller regional operators, as well as…
• FY2025 10-K: …of service procedures that we provide, a decline in reimbursement rates will reduce our net revenues and results of operations. If we fail to manage the complex and lengthy reimbursement process, our revenue, financial condition and results of operations could suffer. Because our business depends upon reimbursement…
• HALO (HALOZYME THERAPEUTICS, INC.)
• FY2025 10-K: …pricing, discounting, marketing and promotion and other business arrangements. These laws may impact, among other things, our current activities with principal investigators and research subjects, as well as sales, marketing and education programs. Many states have similar healthcare fraud and abuse laws, some of…
• FY2025 10-K: …and results of operations. To help patients afford certain of our products, we offer discount, rebate, and co-pay coupon programs. CMS recently has issued a regulation imposing additional obligations on manufacturers in order to continue excluding such programs from government pricing calculations to avoid payment of…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Novo Nordisk Q1 2026 results and January 2026 launch pricing · Novo Nordisk Q1 2026 company announcement; Novo Nordisk financial calendar · Novo Nordisk Q1 2026 company announcement · Novo Nordisk launch announcement and US list pricing, January 2026 · Novo Nordisk Q1 2026 results · Novo Nordisk NDA submission announcement, December 18, 2025 · Novo Nordisk announcement, ISTH 2026 · Novo Nordisk share repurchase programme announcements, 2026 · White House announcement of the Lilly and Novo Nordisk agreements, November 6, 2025 · Novo Nordisk statements following the pricing agreement · Health Canada generic semaglutide approvals, April and May 2026 · Novo Nordisk trial results announcement, February 2026 · reported Eli Lilly orforglipron pricing plans, January 2026 · Novo Nordisk financial calendar · reported Eli Lilly orforglipron launch expectations, January 2026